These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 11990789

  • 1. Genetic studies of MIS signalling in sexual development.
    Jamin SP, Arango NA, Mishina Y, Behringer RR.
    Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
    [Abstract] [Full Text] [Related]

  • 2. The müllerian inhibitor and mammalian sexual development.
    Behringer RR.
    Philos Trans R Soc Lond B Biol Sci; 1995 Nov 29; 350(1333):285-8; discussion 289. PubMed ID: 8570693
    [Abstract] [Full Text] [Related]

  • 3. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK.
    Development; 2006 Jun 29; 133(12):2359-69. PubMed ID: 16687449
    [Abstract] [Full Text] [Related]

  • 4. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
    Ingraham HA, Hirokawa Y, Roberts LM, Mellon SH, McGee E, Nachtigal MW, Visser JA.
    Recent Prog Horm Res; 2000 Jun 29; 55():53-67; discussion 67-8. PubMed ID: 11036933
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Paracrine-mediated apoptosis in reproductive tract development.
    Roberts LM, Hirokawa Y, Nachtigal MW, Ingraham HA.
    Dev Biol; 1999 Apr 01; 208(1):110-22. PubMed ID: 10075845
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor.
    Imbeaud S, Faure E, Lamarre I, Mattéi MG, di Clemente N, Tizard R, Carré-Eusèbe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY.
    Nat Genet; 1995 Dec 01; 11(4):382-8. PubMed ID: 7493017
    [Abstract] [Full Text] [Related]

  • 9. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.
    Clin Cancer Res; 2006 Mar 01; 12(5):1593-8. PubMed ID: 16533786
    [Abstract] [Full Text] [Related]

  • 10. The in vivo roles of müllerian-inhibiting substance.
    Behringer RR.
    Curr Top Dev Biol; 1994 Mar 01; 29():171-87. PubMed ID: 7828438
    [Abstract] [Full Text] [Related]

  • 11. Anti-Müllerian hormone receptor defect.
    di Clemente N, Belville C.
    Best Pract Res Clin Endocrinol Metab; 2006 Dec 01; 20(4):599-610. PubMed ID: 17161334
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
    Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK.
    Mol Endocrinol; 2001 Jun 01; 15(6):946-59. PubMed ID: 11376113
    [Abstract] [Full Text] [Related]

  • 14. [Genetics and molecular pathology of anti-Mullerian hormone and its receptor].
    Picard JY, Belville C.
    J Soc Biol; 2002 Jun 01; 196(3):217-21. PubMed ID: 12462075
    [Abstract] [Full Text] [Related]

  • 15. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.
    Clin Cancer Res; 1999 Nov 01; 5(11):3488-99. PubMed ID: 10589763
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies.
    Shah PC, Simpson BB, Donahoe PK.
    Semin Pediatr Surg; 1996 Aug 01; 5(3):182-90. PubMed ID: 8858765
    [Abstract] [Full Text] [Related]

  • 20. AMH and AMH receptor defects in persistent Müllerian duct syndrome.
    Josso N, Belville C, di Clemente N, Picard JY.
    Hum Reprod Update; 2005 Aug 01; 11(4):351-6. PubMed ID: 15878900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.